La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Corix Bioscience a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Corix Bioscience..

Corix Bioscience (OTC:CXBS) Azioni, Catena delle Opzioni

Corix Bioscience Inc is a United States-based research and development firm of cannabidiol (CBD) products and treatments. It is engaged in the business of producing organic CBD oil used for medical applications and treatments. In addition, the group is also focused on the production of tetrahydrocannabivarin oil. The company is focused on operations in Oregon, California, and Nevada, United States.

CORIX BIOSCIENCE INC by Corix Bioscience, Inc.

Corix Bioscience Inc

Baird analyst Rob Oliver maintains Pros Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRO#NYSE">PRO</a>) with a Outperform and lowers the price target from $30 to $27.

News

Price Target

Analyst Ratings

Baird Maintains Outperform on Pros Holdings, Lowers Price Target to $27

Needham analyst Joseph Stringer reiterates Vaxcyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCVX#NASDAQ">PCVX</a>) with a Buy and maintains $90 price target.

Reiteration

PCVX

Needham Reiterates Buy on Vaxcyte, Maintains $90 Price Target

Guidance

SNWV

SANUWAVE Health Prelim. Q1 Revenues $9.1M-$9.3M, Up 57-61% Over Q1 2024

Baird analyst David Koning maintains Cognizant Tech Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSH#NASDAQ">CTSH</a>) with a Neutral and lowers the price target from $90 to $78.

CTSH

Baird Maintains Neutral on Cognizant Tech Solns, Lowers Price Target to $78

Needham analyst Joseph Stringer reiterates Ionis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) with a Buy and maintains $60 price target.

IONS

Needham Reiterates Buy on Ionis Pharmaceuticals, Maintains $60 Price Target

Marvell Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) is making a clean break from its automotive ambitions, and JPMorgan's Harlan Sur thinks that's exactly the kind of focus <a href="https://www.benzinga.com/quote/MRVL/news">investors should be betting on</a>.
Following the company's $2.5 billion sale of its Automotive Ethernet business to Infineon Technologies AG, Sur reiterated an Overweight rating and placed a $130 price target by December 2025, implying a 155% upside from Friday's close at $51.
<h2 class="wp-block-heading">AI Gets The Green Light</h2>
While growing fast, the automotive Ethernet business isn't expected to account for more than 2-3% of Marvell's revenue mix in 2026.
Meanwhile, the company's AI and data center portfolio is growing at a 30-40% annual clip, notes Sur. In short, this isn't about dumping a promising segment &#8211; it's about clearing the runway for a higher-growth flight path.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44625829/jpmorgan-says-broadcom-marvell-could-dominate-ais-next-frontier-heres-why">JPMorgan Says Broadcom, Marvell Could Dominate AI&#8217;s Next Frontier — Here&#8217;s Why</a>
<h2 class="wp-block-heading">High Valuation, Low Drag</h2>
The deal was struck at a 10.5x sales multiple, a healthy premium for a business expected to bring in $225 to $250 million in FY26 with 60% gross margins. 
Sur says the transaction could be slightly accretive to earnings &#8211; boosting Marvell's EPS by 5 to 10 cents per share—especially if the cash is channeled into stock buybacks.
<h2 class="wp-block-heading">Clean Break, Clear Strategy</h2>
Marvell's exit from the auto space follows its October quarter restructuring, where it began shifting investments away from enterprise networking, carrier infrastructure and automotive.
The company is now focused on AI and accelerated computing &#8211; a theme Sur sees as key to unlocking long-term value.
Marvell may have built the auto business from scratch over eight years, but with a $2.5 billion payday and a 155% potential upside, the real race is in AI, and Marvell just hit the gas.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44653936/broadcom-and-marvell-poised-for-growth-as-nvidias-cpo-push-faces-delays-analyst-reveals">Rising Tide Of AI Is So Strong That Semiconductor Optical Industry Projects $30 Billion Total Addressable Market By 2029</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Long Ideas

Asset Sales

Tech

Trading Ideas

MRVL

Marvell Plays AI Hardball: Divestiture Sparks 155% Upside, Says Analyst

Tesla Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) <a href="https://www.benzinga.com/markets/equities/25/04/44679026/elon-musk-made-unsucessful-appeals-to-trump-to-reverse-new-tariffs-as-tesla-likely-to-take-a-hit-report">brutal year continues</a>.
The electric car company&#8217;s <a href="https://www.benzinga.com/quote/TSLA/news">stock is down</a> nearly 38.5% year to date, as the electric vehicle giant struggles with falling sales, stiffening competition, and political noise that's increasingly hard to ignore.
"This has been a rough stretch for those traders who have been bullish on the stock," said Ed Egilinsky, Managing Director at Direxion, in an exclusive interview with Benzinga.
"Increasing competition, declining sales, and the softening in consumer demand have all contributed to the decline," he said. Despite the drawdown, some active traders think the worst may be behind Tesla — at least in the short term.
Read Also: <a href="https://www.benzinga.com/markets/25/04/44680269/elon-musks-net-worth-dives-below-300-billion-for-the-first-time-since-november-amid-tesla-attacks-and-tariff-woes">Elon Musk&#8217;s Net Worth Dives Below $300 Billion For The First Time Since November Amid Tesla Attacks And Tariff Woes</a>
<h2 class="wp-block-heading">Tesla Stock Technicals Still Flashing Red</h2>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0408"><img loading="lazy" decoding="async" width="629" height="491" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08070710/Screenshot-2025-04-08-at-4.36.58-PM.png" alt="" class="wp-image-861668" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08070710/Screenshot-2025-04-08-at-4.36.58-PM.png 629w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/08070710/Screenshot-2025-04-08-at-4.36.58-PM-300x234.png 300w" sizes="(max-width: 629px) 100vw, 629px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0408" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Tesla stock has shown signs of overselling, hovering at $237.27 as of Tuesday morning, with its RSI (relative strength index) reading at 39.81. 
While not technically oversold yet, it&#8217;s inching closer to that 30 threshold. Technically, things look bleak: TSLA stock trades well below its 8-, 20-, 50-, and 200-day simple moving averages, all flashing bearish signals. 
Its MACD (moving average convergence/divergence) indicator is negative at 12.37, reinforcing the bearish setup.
<h2 class="wp-block-heading">Musk's Politics: A Double-Edged Sword</h2>
Beyond the numbers, CEO Elon Musk's political entanglements are casting a unique shadow over the stock. 
"Tesla stock is unique in the sense that Musk has ties to the current administration," Egilinsky noted, a factor that <a href="https://www.benzinga.com/markets/25/04/44657033/elon-musk-loses-11-billion-as-tesla-stock-plummets-in-wake-of-new-trump-tariffs">could become more volatile</a> heading into election season.
Curiously, <a href="https://www.theguardian.com/us-news/2025/apr/02/elon-musk-trump-doge">rumors</a> last week that Musk might scale back his advisory role with DOGE coincided with a rally in the stock.
<h2 class="wp-block-heading">Some See A Short-Term Rebound</h2>
Still, for those betting on a turnaround, "some feel the stock is oversold short term," Egilinsky said.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44680723/despite-tariff-turmoil-bitcoin-outperforms-magnificent-7-stocks-in-2025-records-smaller-losses-than-nvidia-tesla-apple">Despite Tariff Turmoil, Bitcoin Outperforms &#8216;Magnificent 7&#8217; Stocks In 2025 — Records Smaller Losses Than Nvidia, Tesla, Apple</a></li>
</ul>
Image: Shutterstock

Technicals

Exclusives

Interview

TSLA

EXCLUSIVE: Tesla Bulls Are Bruised Not Beaten, Says Direxion's Egilinsky

WIIM

Petroleo Brasileiro shares are trading higher after the company CEO stated they may not change fuel prices despite international developments when asked by Brazil's energy minister.

U.S. stock futures were higher this morning, with the Dow futures gaining more than 900 points on Tuesday.
Shares of The Greenbrier Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBX#NYSE">GBX</a>) fell sharply in today's pre-market trading as the company <a href="https://www.benzinga.com/quote/GBX/earnings">posted downbeat results for its second quarter.</a>
Greenbrier reported quarterly earnings of $1.56 per share which missed the analyst consensus estimate of $1.78 per share. The company reported quarterly sales of $762.100 million which missed the analyst consensus estimate of $898.530 million.
Greenbrier shares dipped 3.9% to $43.00 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>CVRx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) shares dipped 29.8% to $8.10 in today's pre-market trading after the company reported preliminary first quarter 2025 financial results.</li>
<li>Collective Mining Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNL#NYSE">CNL</a>) declined 12.2% to $7.31 in pre-market trading.</li>
<li>InnovAge Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) fell 11.2% to $2.70 in pre-market trading after gaining over 7% on Monday.</li>
<li>PureTech Health plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTC#NASDAQ">PRTC</a>) dipped 11% to $16.02 in pre-market trading.</li>
<li>Emerald Holding, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EEX#NYSE">EEX</a>) fell 7.5% to $3.2100 in pre-market trading.</li>
<li>Celcuity Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) dipped 7.1% to $8.51 in pre-market trading. Celcuity recently reported a year-over-year decrease in fourth-quarter EPS results.</li>
<li>RPM International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) fell 5.9% to $100.40 in pre-market trading following weaker-than-expected quarterly results.</li>
<li>Maze Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAZE#NASDAQ">MAZE</a>) fell 4.5% to $8.52 in pre-market trading.</li>
<li>Enliven Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) declined 3.8% to $17.20 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44678688/dow-falls-for-3rd-session-amid-trumps-tariff-threats-as-apple-tesla-decline-greed-index-remains-in-extreme-fear-zone">Dow Falls For 3rd Session Amid Trump&#8217;s Tariff Threats As Apple, Tesla Decline: Greed Index Remains In &#8216;Extreme Fear&#8217; Zone</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Movers

CELC

CVRX

ELVN

INNV

MAZE

PRTC

Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Biotech

General

SXTP

Sixty Degrees Pharmaceuticals Announces Patent License Agreement With Yale School Of Medicine And Yale School Of Public Health  For The Development And Commercialization Of Tafenoquine In Babesiosis

Peabody Energy shares are trading higher amid President Trump's announcement to expand U.S. coal mining and usage to power data centers and AI.

CINCINNATI, April 08, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) ("Onconetix" or the "Company") (formerly Blue Water Biotech Inc.) and Ocuvex Therapeutics, Inc. ("Ocuvex"), a privately held biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates to address highly prevalent diseases in need of new treatment options, today announced that they have signed a Non-Binding Letter of Intent contemplating a potential business combination transaction with Ocuvex.
Andrew J. Oakley, Chairman of the Board of Onconetix, stated, "We are excited about the opportunity to combine forces with Ocuvex, whose pipeline of commercial and late clinical stage ophthalmic assets will immediately expand our reach beyond oncology , enhancing shareholder value."
Anthony W. Amato, President, CEO of Ocuvex, commented, "With an already FDA approved product, and late stage clinical assets, we believe that combining with Onconetix will allow us to broaden access to capital while continuing to focus on innovation and customer satisfaction. This is an exciting new chapter for our employees, customers, and stakeholders."
Onconetix and Ocuvex will continue negotiations to enter into a definitive agreement. Upon closing of the proposed transaction, Onconetix will acquire all the issued and outstanding equity interests of Ocuvex in exchange for newly issued shares of common stock of Onconetix. Immediately following the closing of the proposed transaction, the pre-closing Ocuvex equity holders will own approximately 90% of the equity interests in Onconetix.&nbsp;&nbsp;
The Letter of Intent only represents a mutual indication of interest regarding the proposed transaction, and the terms of any such transaction are subject to a number of contingencies, including the completion of due diligence and the negotiation and execution of a definitive agreement. Completion of the proposed transaction will be subject to customary conditions, including (i) the completion of adequate financing, and (ii) the obtainment of applicable regulatory, stockholder and third-party approvals. There can be no assurance that a definitive agreement will be executed or that the proposed transaction will completed as proposed, or at all.

ONCO

Onconetix Signs Letter Of Intent Contemplating Business Combination With Ocuvex Therapeutics

Wells Fargo analyst Roger Read downgrades Liberty Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LBRT#NYSE">LBRT</a>) from Overweight to Equal-Weight and lowers the price target from $20 to $11.

Downgrades

LBRT

Wells Fargo Downgrades Liberty Energy to Equal-Weight, Lowers Price Target to $11

CVS Health shares are trading higher after the company announced changes to management and Medicare increased advantage payment rates.

Wells Fargo analyst Roger Read upgrades Schlumberger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) from Equal-Weight to Overweight and lowers the price target from $46 to $44.

Upgrades

Wells Fargo Upgrades Schlumberger to Overweight, Lowers Price Target to $44

Needham analyst Joseph Stringer reiterates Inozyme Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INZY#NASDAQ">INZY</a>) with a Buy and maintains $15 price target.

INZY

Needham Reiterates Buy on Inozyme Pharma, Maintains $15 Price Target

LUNR

Intuitive Machines Selects SpaceX's Falcon 9 Rocket To Launch Its IM-4 Mission From Florida

Market-Moving Exclusives

BLNE

EXCLUSIVE: Beeline Holdings Tells Benzinga 'Beeline's originations increased by $46M in 2024, up 38%—versus industry growth of 9%'

EXCLUSIVE: Beeline Holdings Tells Benzinga Co. Announces That Its 2024 Growth In Origination Volume Outpaced The Broader Industry By 29%

On Tuesday, fintech mortgage lender Beeline Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNE#NASDAQ">BLNE</a>) reported that its 2024 origination volume growth outpaced the broader industry by 29%, clocking originations of just under $200 million.
According to the Mortgage Bankers Association (MBA), U.S. mortgage originations hit $1.79 trillion in 2024, marking a recovery from the 2022 downturn. Since the Q4 2022 low, Beeline has averaged nearly 20% quarterly revenue growth through Q4 2024, the company said.
Founded in the second half of 2020, Beeline closed its first full year in 2021 with $7.8 million in revenue. Despite rising interest rates and a prolonged mortgage downturn that began in October 2021, the company grew revenue by 33.5% in 2024 compared to 2023—defying broader industry declines.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/03/44471561/exclusive-beeline-ceo-buys-stock-at-205-premium-in-series-g-offering" rel="noreferrer noopener">Beeline CEO Buys Stock At 205% Premium In Series G Offering</a>
Looking ahead, the MBA's baseline forecast projects 30-year mortgage rates to end 2025 at approximately 5.9%. Beeline sees this as a favorable backdrop and believes it is well-positioned for accelerated growth through 2027.
Beeline Co-founder and CEO Nick Liuzza reflected on the company's early challenges, noting they entered the market during a turbulent time.
"Our timing wasn't ideal, but we've built the company to withstand volatility," he said.
"We caught a favorable market to close out 2021, but like the rest of the industry, we were hit by rising rates and a shortage of single-family homes. The difference is—we didn't slow down. We kept building software, expanded our product suite, and diversified our lending capabilities. Now, we're positioned to move quickly. With rates coming down last week, our timing as a public company seems excellent."
Price Action: BLNE shares were trading lower by 1.21% by $1.63 in premarket trading at the last check on Tuesday.

Fintech news covering the emerging Financial Technology services sector

Fintech

EXCLUSIVE: Beeline Clocks About $200 Million Mortgage Origination Volume In 2024

Corix Bioscience

Comments

Corix Bioscience

Corix Bioscience (CXBS) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO